Lecigen

Entacapone/Levodopa/Carbidopa, the active ingredient in Lecigen, is a Levodopa/Carbidopa/Entacapone combination presented as a tablet for intestinal use. It treats Parkinson's disease in adults by improving motor control and reducing off‑periods. GNH USA supplies Lecigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lecigen is a fixed‑dose combination that targets the dopaminergic pathway in Parkinson's disease. It is used to manage motor symptoms and fluctuations in patients receiving levodopa therapy. - Parkinson's disease (motor fluctuations): reduces off‑time and stabilises symptom control. - Parkinson's disease (overall symptom control): improves gait, rigidity and tremor. - Parkinson's disease (adjunct therapy): allows lower levodopa dosing and may delay dose escalation.

Lecigen may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dyskinesia: involuntary movements, especially at higher levodopa levels. - Orthostatic hypotension: dizziness upon standing. - Dizziness: general light‑headedness. - Constipation: reduced bowel motility. - Dry mouth: decreased salivation.

Serious or Rare Side Effects: - Severe liver injury: elevated transaminases, jaundice. - Neuroleptic malignant‑like syndrome: high fever, muscle rigidity. - Severe allergic reactions: rash, angioedema, anaphylaxis. - Hyperpyrexia: uncontrolled high fever. - Severe depression or suicidal thoughts. - Hallucinations: visual or auditory disturbances.

When prescribing Lecigen, clinicians should consider several safety aspects. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution; monitor liver enzymes regularly. - Cardiovascular disease: observe for hypotension and arrhythmias. - Psychiatric history: watch for mood changes, depression, or hallucinations. - Concomitant MAO‑B inhibitors: avoid due to risk of hypertensive crisis. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Lecigen interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Other COMT inhibitors: additive inhibition may cause excessive levodopa levels. - Anticholinergic agents: increased central side effects.

Moderate Interactions (Monitor Closely): - Antihypertensives: may enhance hypotensive effect. - SSRIs/SNRIs: monitor for serotonin syndrome. - Iron or calcium supplements: can reduce levodopa absorption; separate dosing by at least 2 hours.